Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.
Identifieur interne : 001589 ( PubMed/Curation ); précédent : 001588; suivant : 001590Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.
Auteurs : Helene Bihan [France] ; Winda L. Ng [Australie] ; Dianna J. Magliano [Australie] ; Jonathan E. Shaw [Australie]Source :
- Diabetes research and clinical practice [ 1872-8227 ] ; 2016.
Descripteurs français
- KwdFr :
- Diabète de type 2 (sang), Diabète de type 2 (traitement médicamenteux), Femelle, Glycémie (métabolisme), Humains, Hypoglycémiants (usage thérapeutique), Hémoglobine A glycosylée (métabolisme), Incrétines (usage thérapeutique), Inhibiteurs de la dipeptidyl-peptidase IV (usage thérapeutique), Mâle, Récepteur du peptide-1 similaire au glucagon (agonistes), Résultat thérapeutique.
- MESH :
- agonistes : Récepteur du peptide-1 similaire au glucagon.
- métabolisme : Glycémie, Hémoglobine A glycosylée.
- sang : Diabète de type 2.
- traitement médicamenteux : Diabète de type 2.
- usage thérapeutique : Hypoglycémiants, Incrétines, Inhibiteurs de la dipeptidyl-peptidase IV.
- Femelle, Humains, Mâle, Résultat thérapeutique.
English descriptors
- KwdEn :
- Blood Glucose (metabolism), Diabetes Mellitus, Type 2 (blood), Diabetes Mellitus, Type 2 (drug therapy), Dipeptidyl-Peptidase IV Inhibitors (therapeutic use), Female, Glucagon-Like Peptide-1 Receptor (agonists), Hemoglobin A, Glycosylated (metabolism), Humans, Hypoglycemic Agents (therapeutic use), Incretins (therapeutic use), Male, Treatment Outcome.
- MESH :
- chemical , agonists : Glucagon-Like Peptide-1 Receptor.
- chemical , metabolism : Blood Glucose, Hemoglobin A, Glycosylated.
- blood : Diabetes Mellitus, Type 2.
- drug therapy : Diabetes Mellitus, Type 2.
- chemical , therapeutic use : Dipeptidyl-Peptidase IV Inhibitors, Hypoglycemic Agents, Incretins.
- Female, Humans, Male, Treatment Outcome.
Abstract
To identify the determinants of efficacy of glucagon-like peptide-1 receptor agonists (GLP-1A) and dipeptidyl peptidase-4 inhibitors (DPP-4I).
DOI: 10.1016/j.diabres.2016.08.011
PubMed: 27622682
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001611
Links to Exploration step
pubmed:27622682Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.</title><author><name sortKey="Bihan, Helene" sort="Bihan, Helene" uniqKey="Bihan H" first="Helene" last="Bihan">Helene Bihan</name><affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; Department of Endocrinology, Diabetology and Metabolic Disease, Avicenne Hospital, SMBH, Paris 13, Bobigny, France; UMR U557 Inserm/U1125 Inra/CNAM/Université Paris 13, Sorbonne Paris Cité, Bobigny, France. Electronic address: helene.bihan@aphp.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; Department of Endocrinology, Diabetology and Metabolic Disease, Avicenne Hospital, SMBH, Paris 13, Bobigny, France; UMR U557 Inserm/U1125 Inra/CNAM/Université Paris 13, Sorbonne Paris Cité, Bobigny</wicri:regionArea></affiliation></author><author><name sortKey="Ng, Winda L" sort="Ng, Winda L" uniqKey="Ng W" first="Winda L" last="Ng">Winda L. Ng</name><affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria</wicri:regionArea></affiliation></author><author><name sortKey="Magliano, Dianna J" sort="Magliano, Dianna J" uniqKey="Magliano D" first="Dianna J" last="Magliano">Dianna J. Magliano</name><affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria</wicri:regionArea></affiliation></author><author><name sortKey="Shaw, Jonathan E" sort="Shaw, Jonathan E" uniqKey="Shaw J" first="Jonathan E" last="Shaw">Jonathan E. Shaw</name><affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27622682</idno><idno type="pmid">27622682</idno><idno type="doi">10.1016/j.diabres.2016.08.011</idno><idno type="wicri:Area/PubMed/Corpus">001611</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001611</idno><idno type="wicri:Area/PubMed/Curation">001589</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001589</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.</title><author><name sortKey="Bihan, Helene" sort="Bihan, Helene" uniqKey="Bihan H" first="Helene" last="Bihan">Helene Bihan</name><affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; Department of Endocrinology, Diabetology and Metabolic Disease, Avicenne Hospital, SMBH, Paris 13, Bobigny, France; UMR U557 Inserm/U1125 Inra/CNAM/Université Paris 13, Sorbonne Paris Cité, Bobigny, France. Electronic address: helene.bihan@aphp.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; Department of Endocrinology, Diabetology and Metabolic Disease, Avicenne Hospital, SMBH, Paris 13, Bobigny, France; UMR U557 Inserm/U1125 Inra/CNAM/Université Paris 13, Sorbonne Paris Cité, Bobigny</wicri:regionArea></affiliation></author><author><name sortKey="Ng, Winda L" sort="Ng, Winda L" uniqKey="Ng W" first="Winda L" last="Ng">Winda L. Ng</name><affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria</wicri:regionArea></affiliation></author><author><name sortKey="Magliano, Dianna J" sort="Magliano, Dianna J" uniqKey="Magliano D" first="Dianna J" last="Magliano">Dianna J. Magliano</name><affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria</wicri:regionArea></affiliation></author><author><name sortKey="Shaw, Jonathan E" sort="Shaw, Jonathan E" uniqKey="Shaw J" first="Jonathan E" last="Shaw">Jonathan E. Shaw</name><affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria</wicri:regionArea></affiliation></author></analytic><series><title level="j">Diabetes research and clinical practice</title><idno type="eISSN">1872-8227</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Blood Glucose (metabolism)</term><term>Diabetes Mellitus, Type 2 (blood)</term><term>Diabetes Mellitus, Type 2 (drug therapy)</term><term>Dipeptidyl-Peptidase IV Inhibitors (therapeutic use)</term><term>Female</term><term>Glucagon-Like Peptide-1 Receptor (agonists)</term><term>Hemoglobin A, Glycosylated (metabolism)</term><term>Humans</term><term>Hypoglycemic Agents (therapeutic use)</term><term>Incretins (therapeutic use)</term><term>Male</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Diabète de type 2 (sang)</term><term>Diabète de type 2 (traitement médicamenteux)</term><term>Femelle</term><term>Glycémie (métabolisme)</term><term>Humains</term><term>Hypoglycémiants (usage thérapeutique)</term><term>Hémoglobine A glycosylée (métabolisme)</term><term>Incrétines (usage thérapeutique)</term><term>Inhibiteurs de la dipeptidyl-peptidase IV (usage thérapeutique)</term><term>Mâle</term><term>Récepteur du peptide-1 similaire au glucagon (agonistes)</term><term>Résultat thérapeutique</term></keywords><keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en"><term>Glucagon-Like Peptide-1 Receptor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Blood Glucose</term><term>Hemoglobin A, Glycosylated</term></keywords><keywords scheme="MESH" qualifier="agonistes" xml:lang="fr"><term>Récepteur du peptide-1 similaire au glucagon</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Diabetes Mellitus, Type 2</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Diabetes Mellitus, Type 2</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Glycémie</term><term>Hémoglobine A glycosylée</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Diabète de type 2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dipeptidyl-Peptidase IV Inhibitors</term><term>Hypoglycemic Agents</term><term>Incretins</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Diabète de type 2</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Hypoglycémiants</term><term>Incrétines</term><term>Inhibiteurs de la dipeptidyl-peptidase IV</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Male</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To identify the determinants of efficacy of glucagon-like peptide-1 receptor agonists (GLP-1A) and dipeptidyl peptidase-4 inhibitors (DPP-4I).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27622682</PMID><DateCreated><Year>2016</Year><Month>09</Month><Day>13</Day></DateCreated><DateCompleted><Year>2017</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8227</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><PubDate><Year>2016</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Diabetes research and clinical practice</Title><ISOAbbreviation>Diabetes Res. Clin. Pract.</ISOAbbreviation></Journal><ArticleTitle>Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.</ArticleTitle><Pagination><MedlinePgn>27-34</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0168-8227(16)30434-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.diabres.2016.08.011</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To identify the determinants of efficacy of glucagon-like peptide-1 receptor agonists (GLP-1A) and dipeptidyl peptidase-4 inhibitors (DPP-4I).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">MEDLINE and EMBASE were searched between 01/01/2011 and 15/08/2014 for randomized controlled trials of 12-52weeks' duration, which reported the change in glycated hemoglobin (HbA1c) from baseline as the primary end point, and reported data about predictors of efficacy of incretins.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 4172 studies found, 77 studies reported data on baseline HbA1c, age, sex, ethnicity, body mass index (BMI), and history of diabetes in relation to change in HbA1c. For DPP-4I, 37 out of 47 studies reported a greater decrease in HbA1c among patients with higher baseline HbA1c. Most DPP-4I studies reported no variation in efficacy in regard to demographic characteristics or BMI. Among 17 studies reporting on GLP-1A, baseline higher HbA1c was reported as predictive of a greater response in 7 out of 9 studies; 13 studies reported data about other factors, without consistent findings.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Current evidence suggests that higher baseline HbA1c is associated with a greater efficacy of both DPP-4I and GLP-1A therapies in lowering HbA1c. The roles of other potential predictors are less consistent across studies and require further investigation.</AbstractText><CopyrightInformation>Copyright © 2016. Published by Elsevier Ireland Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bihan</LastName><ForeName>Helene</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; Department of Endocrinology, Diabetology and Metabolic Disease, Avicenne Hospital, SMBH, Paris 13, Bobigny, France; UMR U557 Inserm/U1125 Inra/CNAM/Université Paris 13, Sorbonne Paris Cité, Bobigny, France. Electronic address: helene.bihan@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Winda L</ForeName><Initials>WL</Initials><AffiliationInfo><Affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magliano</LastName><ForeName>Dianna J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Jonathan E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Diabetes Res Clin Pract</MedlineTA><NlmUniqueID>8508335</NlmUniqueID><ISSNLinking>0168-8227</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054873">Dipeptidyl-Peptidase IV Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067757">Glucagon-Like Peptide-1 Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Hemoglobin A, Glycosylated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054795">Incretins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054873" MajorTopicYN="N">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067757" MajorTopicYN="N">Glucagon-Like Peptide-1 Receptor</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Hemoglobin A, Glycosylated</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054795" MajorTopicYN="N">Incretins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Determinant factors</Keyword><Keyword MajorTopicYN="N">Diabetes</Keyword><Keyword MajorTopicYN="N">Efficacy</Keyword><Keyword MajorTopicYN="N">Incretin therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>03</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>06</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>08</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27622682</ArticleId><ArticleId IdType="pii">S0168-8227(16)30434-X</ArticleId><ArticleId IdType="doi">10.1016/j.diabres.2016.08.011</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001589 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001589 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:27622682
|texte= Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:27622682" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |